DDX53

(redirected from CT26)

DDX53

A gene on chromosome Xp22.11 that encodes a putative ATP-binding helicase with a conserved Asp-Glu-Ala-Asp (DEAD) motif.
Mentioned in ?
References in periodicals archive ?
In addition animals with CT26 colorectal tumours had 27% inhibition of tumour growth when treated with BNC105 as a monotherapy and 14% inhibition in tumour growth when treated with an antibody targeting CTLA4.
The anti-cancer activity of AG was evaluated by CT26 colon cancer-bearing BALB/c mice.
7, murine YAC-1 and murine colon cancer cells CT26 were obtained from the Food Industry Research and Development Institute (Hsinchu, Taiwan), and were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, USA), and supplemented with 10% (v/v) foetal bovine serum (FBS, Gibco, USA), 100 [micro]g/ml of streptomycin, and 100U/ml penicillin (Gibco, USA) at 37[degrees]C in a humidified atmosphere containing 5% C[O.
CT26 colon cancer cells were injected into the subcapsule of mouse spleen in positive control group, low, middle and high MCP concentrations groups, except in negative control, to set up a colon cancer liver metastasis model.
CT26 colon cancer cells were injected into the subcapsule of the mouse spleen to establish liver metastasis models of colon cancer, but the mice in the negative control group received no tumor cell injection.
Immunomodulatory activity of NOV-002 potentiates the anti-tumor efficacy of cyclophosphamide in the CT26 murine colon cancer model (Abstract #5620) Drs.
NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models
In this study, the cancer cachexia model was established by subcutaneous transplantation CT26 tumor fragment.
HOLE DEPTH INTERVAL GRADES (m) (m) Cu% Au g/t CT26 6-100 94 0.
However, there is no report to show that DATS induced apoptosis in vitro and inhibited CT26 cancer cells in vivo on a murine allograft animal model.
016) of tumor eradication (57%, n=56) in the murine colon carcinoma CT26 model, as compared to the group treated with cisplatin alone (15%, n=52) or to the group treated with Ad-IL2 alone (28%, n=64).
Treatment of colon carcinoma-bearing mice with either IMOxine or HYB2048 resulted in the development of cellular immunity (cytotoxic T-lymphocyte activity) and humoral immunity (antibodies to beta-gal, an antigen expressed by CT26.